Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 22, 781-782 (2023)
Updates & Corrections
Clarification 06 July 2023: It has been clarified in Table 1 that three of the top 20 biopharma companies (Amgen, Biogen and Gilead Sciences) are defined as biotech companies founded after 1976 in the analyses presented in the article, such as those shown in Figure 1b and 1c. For full details of how each drug is assigned on the basis of company type, see Supplementary Table 2.
A.S. and O.G. declare no competing interests. M.H. is an employee of Novartis and a former employee of Roche and Sanofi. D.H. is a former employee of Roche and Novartis. A.D. is an employee of Johnson & Johnson. This study did not receive external funding and was undertaken independently.